Novel mode of action of c-kit tyrosine kinase inhibitors leading to NK cell-dependent antitumor effects
Open accessThe DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Abstract
Mutant isoforms of the KIT or PDGF receptors expressed by gastrointestinal stromal tumors (GISTs) are considered the therapeutic targets for STI571 (imatinib mesylate; Gleevec), a specific inhibitor of these tyrosine kinase receptors.Case reports of clinical efficacy of Gleevec in GISTs lacking the typical receptor mutations prompted a search for an alternate mode of action.Here we show that Gleevec can act on host DCs to promote NK cell activation.DC-mediated NK cell activation was triggered in vitro and in vivo by treatment of DCs with Gleevec as well as by a loss-of-function mutation of KIT.Therefore, tumors that are refractory to the antiproliferative effects of Gleevec in vitro responded to Gleevec in vivo in an NK cell-dependent manner.Longitudinal studies of Gleevec-treated GIST patients revealed a therapy-induced increase in IFN-γ production by NK cells, correlating with an enhanced antitumor response.These data point to a novel mode of antitumor action for Gleevec.Nonstandard abbreviations used: bi-injection daily (bid); bone marrow-derived DC (BM-DC); break point cluster region/Abelson leukemia virus (BCR/ABL); chronic myelogenous leukemia (CML); c-kit loss-of-function mutation (W/Wv); fms-like tyrosine 3 kinase ligand (FL); gastrointestinal stromal tumor (GIST); progression-free survival (PFS); stem cell factor (SCF); transporter associated with antigen processing (TAP).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Imatinib was arguably the first targeted anticancer agent to demonstrate immunostimulatory effects that are directly linked to NK-cell activation”
From Immunomodulation by targeted anticancer agents (2021) · cites this paper as Borg et al., 2004
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors
Demetri, G. D., von Mehren, M., Blanke, C. D., Van den Abbeele, A. D., Eisenberg, B., Roberts, P. J., Heinrich, M. C., Tuveson, D. A., Singer, S., Janicek, M., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020461 · Cited by 4,389 · cited 1×
“Gleevec administration results in objective (partial or complete) response or stabilization in about 80% of GIST patients (6).”
BackgroundSelf-citationEffectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants
Ruggeri, L., Capanni, M., Urbani, E., Perruccio, K., Shlomchik, W. D., Tosti, A., Posati, S., Rogaia, D., Frassoni, F., Aversa, F., et al. (2002) · Science · doi:10.1126/science.1068440 · Cited by 3,380 · cited 1×
“The renaissance of interest in NK cells in tumor immunosurveillance can be attributed to the discovery of stressinduced ligands for receptors that activate NK cells (23–25) and to the relevance of interactions between MHC class I molecules and killer inhibitory receptors in mismatched hematopoietic transplants, which…”
BackgroundActivation of NK Cells and T Cells by NKG2D, a Receptor for Stress-Inducible MICA
Bauer, S., Groh, V., Wu, J., Steinle, A., Phillips, J. H., Lanier, L. L., & Spies, T. (1999) · Science · doi:10.1126/science.285.5428.727 · Cited by 2,999
PDGFRA Activating Mutations in Gastrointestinal Stromal Tumors
Heinrich, M. C., Corless, C. L., Duensing, A., McGreevey, L., Chen, C.-J., Joseph, N., Singer, S., Griffith, D. J., Haley, A., Town, A., et al. (2003) · Science · doi:10.1126/science.1079666 · Cited by 2,301 · cited 1×
“Somatic gain-of-function mutations of the c-kit protooncogene are found in 85% of GISTs (1), and recently, mutations of the PDGFRα chain were reported in 35% of the GISTs lacking the KIT mutations (2).”
BackgroundKinase Mutations and Imatinib Response in Patients With Metastatic Gastrointestinal Stromal Tumor
Heinrich, M. C., Corless, C. L., Demetri, G. D., Blanke, C. D., von Mehren, M., Joensuu, H., McGreevey, L. S., Chen, C.-J., Van den Abbeele, A. D., Druker, B. J., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.04.190 · Cited by 2,299 · cited 4×
“GISTs harboring an exon 11 mutation (76% of GISTs) exhibit the highest objective response rate and the longest time to progression (7).”
BackgroundTumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation
Groh, V., Wu, J., Yee, C., & Spies, T. (2002) · Nature · doi:10.1038/nature01112 · Cited by 1,592 · cited 1×
“Notably, in 50% of GIST-bearing patients, a fraction of circulating NK cells showed a downregulation of NKG2D expression at diagnosis (data not shown), which suggests that GISTs secrete soluble NKG2D ligands that might downregulate NKG2D expression on blood NK cells, similarly to the downregulation seen on T cells (30…”
BackgroundCosman, D., Müllberg, J., Sutherland, C. L., Chin, W., Armitage, R., Fanslow, W., Kubin, M., & Chalupny, N. J. (2001) · Immunity · doi:10.1016/s1074-7613(01)00095-4 · Cited by 1,232
Maraskovsky, E., Brasel, K., Teepe, M., Roux, E. R., Lyman, S. D., Shortman, K., & McKenna, H. J. (1996) · The Journal of experimental medicine · doi:10.1084/jem.184.5.1953 · Cited by 1,115 · cited 6×
“Since FL is known to amplify DCs, (14) and since mature DCs have the unique capacity to promote NK cell effector functions including IFN-γ secretion and antitumor effects in vivo (10, 15), we hypothesized that Gleevec could confer an NK cell stimulatory capacity to host DCs. Gleevec enhanced IFN-γ production by NK cel…”
BackgroundInfluentialRae1 and H60 ligands of the NKG2D receptor stimulate tumour immunity
Diefenbach, A., Jensen, E. R., Jamieson, A. M., & Raulet, D. H. (2001) · Nature · doi:10.1038/35093109 · Cited by 1,083
Fernandez, N. C., Lozier, A., Flament, C., Ricciardi-Castagnoli, P., Bellet, D., Suter, M., Perricaudet, M., Tursz, T., Maraskovsky, E., & Zitvogel, L. (1999) · Nature Medicine · doi:10.1038/7403 · Cited by 1,060
Research works printed but not linked: 1
- Van Glabbeke, M.M., et al. 2003. Prognostic factors of toxicity and efficacy in patients with gastro-intes- tinal stromal tumors (GIST) treated with imatinib: A study of the EORTC-STBSG, ISG and AGITG [abstract]. Proc. Am. Soc. Clin. Oncol. 22:3286.
Cited by
Items 101–200 of 302
The interplay between the immune system and chemotherapy: emerging methods for optimizing therapy
Ghiringhelli, F., & Apétoh, L. (2013) · Expert Review of Clinical Immunology · doi:10.1586/1744666x.2014.865520 · Cited by 60
Marín, D., Gabriel, I. H., Ahmad, S., Foroni, L., de Lavallade, H., Clark, R. E., O’Brien, S. J., Sergeant, R., Hedgley, C. A., Milojković, D., et al. (2011) · Leukemia · doi:10.1038/leu.2011.180 · Cited by 53
Dendritic cells and innate defense against tumor cells
Ullrich, E., Menard, C., Flament, C., Terme, M., Mignot, G., Bonmort, M., Plumas, J., Chaperot, L., Chaput, N., & Zitvogel, L. (2008) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2007.10.009 · Cited by 57
Saito, H., Takaya, S., Osaki, T., & Ikeguchi, M. (2012) · Gastric Cancer · doi:10.1007/s10120-012-0210-1 · Cited by 53
“In fact, NK cells may participate in tumor immune surveillance, particularly in leukemia [25], neuroblastoma [26], and gastrointestinal stromal tumors [27].”
BackgroundKomita, H., Koido, S., Hayashi, K., Kan, S., Ito, M., Kamata, Y., Suzuki, M., & Homma, S. (2015) · Oncology Reports · doi:10.3892/or.2015.4149 · Cited by 55
“It has also been reported that NK cells and the interferon-γ status of GIST patients predict prognosis (9), and imatinib mesylate induced NK cell activation and promoted antitumor immunity to GIST (10).”
BackgroundA Phase I Clinical Trial Evaluating Imatinib Mesylate (Gleevec) in Tumor-Bearing Cats
Lachowicz, J. L., Post, G. S., & Brodsky, E. M. (2005) · Journal of Veterinary Internal Medicine · doi:10.1111/j.1939-1676.2005.tb02778.x · Cited by 50
Systemic cancer therapy: Evolution over the last 60 years
Dy, G. K., & Adjei, A. A. (2008) · Cancer · doi:10.1002/cncr.23651 · Cited by 65
Haberler, C., Gelpí, E., Marosi, C., Rössler, K., Birner, P., Budka, H., & Hainfellner, J. A. (2005) · Journal of Neuro-Oncology · doi:10.1007/s11060-005-4570-9 · Cited by 50
Imatinib and gastrointestinal stromal tumors: Where do we go from here?
Giorgi, U. D., & Verweij, J. (2005) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-04-0302 · Cited by 49
“Longitudinal studies of GIST patients treated with imatinib revealed a therapy-induced increase in IFN-g production by natural killer cells, correlating with an enhanced antitumor response (65).”
BackgroundMignot, G., Ullrich, E., Bonmort, M., Menard, C., Apétoh, L., Taı̈eb, J., Bosisio, D., Sozzani, S., Ferrantini, M., Schmitz, J., et al. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.180.10.6477 · Cited by 55
“Discussion These findings underscore the antitumoral efficacy of associating two NK cell adjuvants, one blocking the c-kit tyrosine kinase of cDC (7) and the IL-2, a major lymphokine-inducing proliferation and activation of T and NK cells (22).”
BackgroundNovel immune modulators used in hematology: impact on NK cells
Krieg, S., & Ullrich, E. (2013) · Frontiers in Immunology · doi:10.3389/fimmu.2012.00388 · Cited by 55
“Further, in a murine model NK cell activation could be induced by imatinib-treated DC in vitro and in vivo (Borg et al., 2004).”
BackgroundInfluentialExploiting antitumor immunity to overcome relapse and improve remission duration
Chen, L. L., Chen, X., Choi, H., Sang, H., Chen, L. C., Zhang, H., Gouw, L. G., Andtbacka, R. H. I., Chan, B. K., Rodesch, C. K., et al. (2011) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-011-1185-1 · Cited by 52
“IM was reported to induce DC-mediated natural killer (NK) cell IFN-c production [32, 33] and potentiate adaptive immunity through IM-off-target inhibition of KIT on DCs [34] and inhibition of Ido [35]; both IM-off-target immunological anti-GIST effects plus IM-inhibition of KIT/PDG FRA signaling contribute to the IM-m…”
BackgroundMethodEmerging therapies for the treatment of pulmonary hypertension
Stenmark, K. R., & Rabinovitch, M. (2010) · Pediatric Critical Care Medicine · doi:10.1097/pcc.0b013e3181c76db3 · Cited by 46
“In addition, imatinib is increasingly appreciated to have important effects in cancer and also in collageninduced arthritis through immunomodulatory effects (35, 37).”
BackgroundResponse to imatinib in villonodular pigmented synovitis (PVNS) resistant to nilotinib
Stacchiotti, S., Crippa, F., Messina, A., Pilotti, S., Gronchi, A., Blay, J., & Casali, P. G. (2013) · Clinical Sarcoma Research · doi:10.1186/2045-3329-3-8 · Cited by 45
Dahlhoff, J., Manz, H., Steinfatt, T., Tascon, J. D., Seebacher, E., Schneider, T., Wilnit, A., Mokhtari, Z., Tabares, P., Böckle, D., et al. (2021) · Leukemia · doi:10.1038/s41375-021-01422-y · Cited by 49
Imatinib and Nilotinib Off-Target Effects on Human NK Cells, Monocytes, and M2 Macrophages
Bellora, F., Dondero, A., Corrias, M. V., Casu, B., Regis, S., Caliendo, F., Moretta, A., Cazzola, M., Elena, C., Vinti, L., et al. (2017) · The Journal of Immunology · doi:10.4049/jimmunol.1601695 · Cited by 44
The Role of Natural Killer (NK) Cells in Acute Coronary Syndrome: A Comprehensive Review
Kumrić, M., Kurir, T. T., Borovac, J. A., & Božić, J. (2020) · Biomolecules · doi:10.3390/biom10111514 · Cited by 48
“demonstrated that imatinib mesylate (c-kit inhibitor [86]) is able to promote NK cell activation via dendritic cells, but not directly [87].”
BackgroundTerme, M., Tartour, É., & Taïeb, J. (2013) · OncoImmunology · doi:10.4161/onci.25156 · Cited by 49
Bauer, S., & Joensuu, H. (2015) · Drugs · doi:10.1007/s40265-015-0440-8 · Cited by 43
“Some studies suggest a role for the natural killer cells in the immune control of GIST [92, 93].”
BackgroundDasatinib promotes Th1-type responses in granzyme B expressing T-cells
Kreutzman, A. S., Ilander, M. M., Porkka, K., Vakkila, J., & Mustjoki, S. M. (2014) · OncoImmunology · doi:10.4161/onci.28925 · Cited by 49
Bourquin, C., Schmidt, L., Lanz, A.-L., Storch, B., Wurzenberger, C., Anz, D., Sandholzer, N., Mocikat, R., Berger, M., Poeck, H., et al. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0901594 · Cited by 43
“Treatment of mice with TLR7-activating oligonucleotides selectively suppressed growth of NK-sensitive tumors, demonstrating that RNA oligonucleotides activate NK immunity (31, 32).”
BackgroundNK cells sense tumors, course of disease and treatments: Consequences for NK-based therapies
Fregni, G., Perier, A., Avril, M., & Caignard, A. (2012) · OncoImmunology · doi:10.4161/onci.1.1.18312 · Cited by 49
“In certain patients, the efficacy of Imatinib was not associated with c-kit mutation in tumor, but dependent on IFNc production by NK cells upon DC-mediated activation.(74) Treatments can also modulate the expression of NK ligands on tumor cells.”
BackgroundSanchez, C., Treut, T. L., Boehrer, A., Knoblauch, B., Imbert, J., Olive, D., & Costello, R. T. (2010) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-010-0898-x · Cited by 53
“Finally, eVects of imatinib on NK cells is probably indirect since imatinib fosters DC/NK reciprocal activation, resulting in the enhancement of NK cells anti-tumoural function [ 76 ].”
BackgroundCebo, C., Rocha, S. D., Wittnebel, S., Turhan, A. G., Jalil, A., Caillat‐Zucman, S., Bourhis, J. H., Chouaı̈b, S., & Caignard, A. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.176.2.864 · Cited by 41
“Treatment with IM has recently been reported to exert diverse effects on innate and adaptative immune responses (44, 46).”
BackgroundMizoguchi, I., Yoshimoto, T., Katagiri, S., Mizuguchi, J., Tauchi, T., Kimura, Y., Inokuchi, K., Ohyashiki, J. H., & Ohyashiki, K. (2013) · Cancer Science · doi:10.1111/cas.12216 · Cited by 45
Tumor-priming converts NK cells to memory-like NK cells
Pal, M., Schwab, L., Yermakova, A., Mace, E. M., Claus, R., Krahl, A.-C., Woiterski, J., Hartwig, U. F., Orange, J. S., Handgretinger, R., et al. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1317411 · Cited by 40
“On the other hand, the plateletderived growth factor-A (PDGF-A) has so far not been associated with NK cell function; however, downregulation of the corresponding c-Kit / PDGF receptor on dendritic cells indeed effectively improves NK cell-triggering.(50) Thus, our data suggest that in addition to enhanced direct anti…”
BackgroundRegulation of mTOR, Metabolic Fitness, and Effector Functions by Cytokines in Natural Killer Cells
Viel, S., Besson, L., Marotel, M., Walzer, T., & Marçais, A. (2017) · Cancers · doi:10.3390/cancers9100132 · Cited by 45
“Tyrosine kinase inhibitors such as Imatinib mesylate have also been shown to enhance NK cell effector potential through unknown mechanisms [80].”
BackgroundDailah, H. G., Hommdi, A. A., Koriri, M. D., Algathlan, E. M., & Mohan, S. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e24559 · Cited by 48
Vujanovic, L. N., Ballard, W., Thorne, S. H., Vujanović, N. L., & Butterfield, L. H. (2012) · OncoImmunology · doi:10.4161/onci.19788 · Cited by 38
“Of the chemokines analyzed, only production of CXCL9/MIG is restricted to LPS/IFNc mDCs.”
BackgroundDufresne, A., Bertucci, F., Penel, N., Cesne, A. L., Bui, B., Tubiana-Hulin, M., Ray-Coquard, I., Cupissol, D., Chevreau, C., Pérol, D., et al. (2010) · British Journal of Cancer · doi:10.1038/sj.bjc.6605783 · Cited by 37
“Imatinib has been previously reported to exert an anti-tumour activity in animal models through the modulation of immune response (Borg et al, 2004).”
BackgroundZeng, Y., Chen, X., Larmonier, N., Larmonier, C. B., Li, G., Sepassi, M., Marron, M., Andreansky, S. S., & Katsanis, E. (2006) · International Journal of Cancer · doi:10.1002/ijc.22150 · Cited by 41
“This may be explained by the ability of imatinib to enhance NK cell function as observed by us (data not shown) and by others.(20) As expected, liver CRCL alone failed to improve survival (Fig.”
Trial Watch: combination of tyrosine kinase inhibitors (TKIs) and immunotherapy
Petrazzuolo, A., Maiuri, M. C., Zitvogel, L., Kroemer, G., & Kepp, O. (2022) · OncoImmunology · doi:10.1080/2162402x.2022.2077898 · Cited by 41
Cellular therapy of cancer with natural killer cells—where do we stand?
Klingemann, H. (2013) · Cytotherapy · doi:10.1016/j.jcyt.2013.03.011 · Cited by 43
“Imatinib can activate NK cell function through dendritic cells (55).”
Wei, Z.-W., Wu, J. T., Huang, W., Li, J., Lu, X., Yuan, Y., Xiong, W., Zhang, X., Wang, W., He, Y., et al. (2020) · EBioMedicine · doi:10.1016/j.ebiom.2020.102850 · Cited by 37
“Borg indicated that imatinib promotes NK cell activation and NK cell-dependant antitumour effects in GISTs [56].”
BackgroundBeyond the Driver Mutation: Immunotherapies in Gastrointestinal Stromal Tumors
Dugage, M. R., Jones, R. L., Trent, J. C., Champiat, S., & Dumont, S. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.715727 · Cited by 40
“This off-target activity seems to be relevant in terms of mechanism of action since the increase in secretion of IFNg after 2 months of treatment with imatinib, which defines a group of “good immunological responders”, is a major prognostic factor (85% PFS at 2 years, vs. only 50% in nonresponders) (62).”
BackgroundInfluentialClinical pharmacokinetics of imatinib mesylate.
Levêque, D., & Maloisel, F. (2005) · PubMed · Cited by 34
Fröbom, R., Berglund, E., Berglund, D., Nilsson, I., Åhlén, J., von Sivers, K., Linder‐Stragliotto, C., Suenaert, P., Karlsson‐Parra, A., & Bränström, R. (2020) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-020-02625-5 · Cited by 35
Therapy-Induced Tumor Immunosurveillance Involves IFN-Producing Killer Dendritic Cells
Ullrich, E., Bonmort, M., Mignot, G., Chaput, N., Taı̈eb, J., Menard, C., Viaud, S., Tursz, T., Kroemer, G., & Zitvogel, L. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-3766 · Cited by 35
“As recently reported, c-kit tyrosine kinase inhibitors such as Gleevec/STI571 can stimulate a host-dependent antitumor activity involving myeloid DC-primed NK cells (2).”
BackgroundTirosin Kinase Inhibitors in Chronic Graft versus Host Disease: From Bench to Bedside
Olivieri, J., Coluzzi, S., Attolico, I., & Olivieri, A. (2011) · The Scientific World JOURNAL · doi:10.1100/2011/924954 · Cited by 37
“However, contradictory results have been reported, as DC treated with Imatinib can also exhibit enhanced APC function and could break the tumor-induced tolerance [129, 130].”
ANTI-TUMOR IMMUNE RESPONSES INDUCED BY RADIOTHERAPY: A REVIEW
Yoshimoto, Y., Kono, K., & Suzuki, Y. (2015) · FUKUSHIMA JOURNAL OF MEDICAL SCIENCE · doi:10.5387/fms.2015-6 · Cited by 29
Immune cells in primary and metastatic gastrointestinal stromal tumors (GIST).
Cameron, S., Gieselmann, M., Blaschke, M., Ramadori, G. P., & FÜZESI, L. (2014) · PubMed Central · Cited by 30
Interactions between the intestinal microbiota and innate lymphoid cells
Chen, V. L., & Kasper, D. L. (2013) · Gut Microbes · doi:10.4161/gmic.27289 · Cited by 34
Bae, J., Kim, S.-J., Kim, M.-J., Oh, S.-O., Chung, J., Kim, S.-H., & Kang, C. (2012) · Cancer Science · doi:10.1111/j.1349-7006.2011.02109.x · Cited by 34
Antitumour and immune-adjuvant activities of protein-tyrosine kinase inhibitors
Seliger, B., Massa, C., Rini, B. I., Ko, J. S., & Finke, J. H. (2010) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2010.02.001 · Cited by 30
Can NK cells be a therapeutic target in human diseases?
Chan, C. J., Andrews, D. M., & Smyth, M. J. (2008) · European Journal of Immunology · doi:10.1002/eji.200838764 · Cited by 36
Immunogenic chemotherapy: discovery of a critical protein through proteomic analyses of tumor cells.
Apétoh, L., Obéid, M., Tesnière, A., Ghiringhelli, F., Fimia, G. M., Piacentini, M., Kroemer, G., & Zitvogel, L. (2007) · PubMed · Cited by 41
GIST Treatment Options after Tyrosine Kinase Inhibitors
Songdej, N., & von Mehren, M. (2014) · Current Treatment Options in Oncology · doi:10.1007/s11864-014-0295-3 · Cited by 30
Chaput, N., Flament, C., Locher, C., Desbois, M., Rey, A., Rusakiewicz, S., Poirier-Colame, V., Pautier, P., Cesne, A. L., Soria, J., et al. (2013) · OncoImmunology · doi:10.4161/onci.23080 · Cited by 36
Immunotherapeutic properties of chemotherapy
Fournier, C., Vargas, T. R., Martin, T. W., Melis, A., & Apétoh, L. (2017) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2017.05.003 · Cited by 30
“Current Opinion in Pharmacology 2017, 35:83–88 promotes DC-mediated NK cell activation [30], while dasatinib, when combined with DC-based vaccine, depletes tumor-infiltrating Treg cells and MDSCs thereby favoring effector T cell expansion [31].”
BackgroundCurrent trends of anticancer immunochemotherapy
Vacchelli, E., Prada, N., Kepp, O., & Galluzzi, L. (2013) · OncoImmunology · doi:10.4161/onci.25396 · Cited by 33
Dendritic cell c-kit signaling and adaptive immunity: implications for the upper airways
Oriss, T. B., Krishnamoorthy, N., Ray, P., & Ray, A. (2013) · Current Opinion in Allergy and Clinical Immunology · doi:10.1097/aci.0000000000000019 · Cited by 29
“Importantly, it was clearly demonstrated that dendritic cells, rather than mast cells, are the pharmacological target of Gleevec in vivo [30].”
BackgroundImatinib: the narrow line between immune tolerance and activation
Mohty, M., Blaise, D., Olive, D., & Gaugler, B. (2005) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2005.07.007 · Cited by 27
Bonmort, M., Ullrich, E., Mignot, G., Jacobs, B., Chaput, N., & Zitvogel, L. (2007) · Biochimie · doi:10.1016/j.biochi.2007.04.014 · Cited by 29
Gastrointestinal Stromal Tumor
Sharma, A. K., Kim, T. S., Bauer, S., & Sicklick, J. K. (2022) · Surgical Oncology Clinics of North America · doi:10.1016/j.soc.2022.03.007 · Cited by 30
Evaluation of Imatinib Mesylate in the Treatment of Pulmonary Arterial Hypertension
Chhina, M. K., Nargues, W., Grant, G. M., & Nathan, S. D. (2009) · Future Cardiology · doi:10.2217/fca.09.54 · Cited by 26
Pellegatta, S., Ianni, N. D., Pessina, S., Paterra, R., Anghileri, E., Eoli, M., & Finocchiaro, G. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20235886 · Cited by 25
“Imatinib mesylate (IM) is responsible for the increase and activation of NK cells when used to treat patients affected by gastrointestinal stromal tumors (GISTs) [36].”
BackgroundAlves, R., McArdle, S., Vadakekolathu, J. N., Gonçalves, A. C., Freitas-Tavares, P., Pereira, A., Almeida, A. M., Sarmento‐Ribeiro, A. B., & Rutella, S. (2020) · Journal of Translational Medicine · doi:10.1186/s12967-019-02194-x · Cited by 24
“The immunological effects of TKIs thus far described are diverse and include M2 reprogramming of TAMs [15]; inhibition of dendritic cell (DC) recovery [16] and effector cytokine production by CD4+ T cells [17]; reduction of IgM-producing memory B cells [18]; T helper 1 (Th1) polarization [19]; triggering of NK functio…”
BackgroundSabado, R. L., Meseck, M. L., & Bhardwaj, N. (2016) · Methods in molecular biology · doi:10.1007/978-1-4939-3387-7_44 · Cited by 24
Ha, Y., Ali, M. A. M., Petersen, M. M., Harmsen, W. S., Therneau, T. M., Lee, H. C., Ryoo, B., Bampoh, S. A., Valles, K. A., Mady, M., et al. (2020) · Hepatology International · doi:10.1007/s12072-020-10076-4 · Cited by 24
Catellani, S., Pierri, I., Gobbi, M., Poggi, A. D., & Zocchi, M. R. (2011) · PLoS ONE · doi:10.1371/journal.pone.0018925 · Cited by 25
“testinal stromal cancer, the response to the drug is also linked to the activation of the immune system with production of antineoplastic cytokines [3–5], thus raising the possibility that this mechanism”
Uchiyama, T., Sato, N., Narita, M., Yamahira, A., Iwabuchi, M., Furukawa, T., Sone, H., & Takahashi, M. (2012) · Hematological Oncology · doi:10.1002/hon.2034 · Cited by 27
“suggested that anti-tumour reactivity of NK cells might be enhanced by crosstalk with host dendritic cells exposed by imatinib [23].”
BackgroundPhase I clinical trial combining imatinib mesylate and IL-2 in refractory cancer patients
Pautier, P., Locher, C., Robert, C., Deroussent, A., Flament, C., Cesne, A. L., Rey, A., Bahleda, R., Ribrag, V., Soria, J., et al. (2013) · OncoImmunology · doi:10.4161/onci.23079 · Cited by 23
“Our group has demonstrated that IM activates natural killer (NK) cells in GIST patients, resulting in improved progression-free survival (PFS).(10,11) These results indicate that the innate immune response is a major and independent PFS predictive factor in patients with advanced GIST receiving IM.”
BackgroundNilotinib Is More Potent than Imatinib for Treating Plexiform Neurofibroma In Vitro and In Vivo
Jiang, W., Freytag, M., Schober, Y., Nockher, W. A., Mautner, V. F., Friedrich, R. E., Manley, P. W., Kluwe, L., & Kurtz, A. (2014) · PLoS ONE · doi:10.1371/journal.pone.0107760 · Cited by 21
“Since off-target effects of imatinib have been reported, among them the effect of activating natural killer cells [23], we measured cytotoxicity of spleen cells of the treated mice.”
BackgroundNew drugs in gastrointestinal stromal tumors
Martín‐Broto, J., & Moura, D. S. (2020) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000642 · Cited by 24
“Preclinical evidences suggest that the characteristics of the immune infiltrate could affect GIST prognosis [26] and response to imatinib [27], indicating that immunotherapy could have a role in the treatment of GIST.”
BackgroundAntitumor activity of imatinib mesylate in neuroblastoma xenografts
Meco, D., Riccardi, A., Servidei, T., Brueggen, J., Gessi, M., Riccardi, R., & Dominici, C. (2005) · Cancer Letters · doi:10.1016/j.canlet.2005.02.054 · Cited by 21
“This hypothesis is further supported by recent reports that showed that imatinib mesylate can also (i) act on host dendritic cells to promote NK cell activation and NK cell-dependent antitumor effect in mice [26], and (ii) inhibit VEGF expression [15].”
ResultShchemelinin, I., Šefc, L., & Nečas, E. (2006) · Folia Biologica · doi:10.14712/fb2006052040137 · Cited by 37
Anticancer effects of imatinib via immunostimulation
Zitvogel, L., & Kroemer, G. (2011) · Nature Medicine · doi:10.1038/nm.2429 · Cited by 20
Fahrner, J., Lahmar, I., Goubet, A., Haddad, Y., Carrier, A., Mazzenga, M., Drubay, D., Silva, C. A. C., Lyon COVID Study Group, de Sousa, E., et al. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-1441 · Cited by 22
Role of Tyrosine Kinase Inhibitors in Tumor Immunology
Nishioka, Y., Aono, Y., & Sone, S. (2010) · Immunotherapy · doi:10.2217/imt.10.79 · Cited by 19
Tumor-Induced Immune Suppression
Gabrilovich, D. I., & Hurwitz, A. A. (2007) · Springer eBooks · doi:10.1007/978-0-387-69118-3 · Cited by 22
Bommarito, D., Martin, A. M., Forcade, É., Nastke, M.-D., Ritz, J., & Bellucci, R. (2016) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-016-1804-y · Cited by 18
“Immunomodulatory drugs such as thalidomide, lenalidomide, pomalidomide or tyrosine kinase inhibitors like imatinib have also shown potent effects on T and NK cell activation [34, 35], while other drugs have immune suppressive activity [36].”
BackgroundImatinib Mesylate — Uncovering a Fast Track to Adaptive Immunity
Smyth, M. J. (2006) · New England Journal of Medicine · doi:10.1056/nejmcibr061878 · Cited by 17
Two-stage phase II study of imatinib mesylate in subjects with refractory or relapsing neuroblastoma
Calafiore, L., Amoroso, L., Alberighi, O. D. C., Luksch, R., Zanazzo, G. A., Castellano, A., Podda, M. G., Dominici, C., Haupt, R., Corrias, M. V., et al. (2013) · Annals of Oncology · doi:10.1093/annonc/mds648 · Cited by 18
“This finding suggests that higher imatinib doses may inhibit the activation of innate immune cells, observed in adult responders [27, 28].”
BackgroundA Lymphocyte-Dependent Mode of Action for Imatinib Mesylate in Experimental Pulmonary Hypertension
Ormiston, M. L., Deng, Y., Rundle, N. T., Bendjelloul, F., Tsoporis, J. N., Parker, T. G., Stewart, D. J., & Courtman, D. W. (2013) · American Journal Of Pathology · doi:10.1016/j.ajpath.2013.01.031 · Cited by 16
Sun, W., Xu, Y., Yan, W., Wang, C., Hu, T., Luo, Z., Zhang, X., Liu, X. Z., & Chen, Y. (2023) · Cancer Medicine · doi:10.1002/cam4.6234 · Cited by 16
Oriss, T. B., Krishnamoorthy, N., Raundhal, M. R., Morse, C., Chakraborty, K., Khare, A., Huff, R., Ray, P., & Ray, A. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1303183 · Cited by 18
“In the periphery, only mature mast cells and NK cells were known to retain c-kit expression (3) prior to our description of its expression on DCs.”
BackgroundKwok, E., Everingham, S., Zhang, S., Greer, P. A., Allingham, J. S., & Craig, A. W. (2012) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-12-0115 · Cited by 18
“, imatinib) on non-KIT–expressing tumors (20).”
Arora, R., Sharma, M., Monif, T., & Iyer, S. (2016) · Cancer Research and Treatment · doi:10.4143/crt.2015.436 · Cited by 15
Campbell, A. M., & Decker, R. H. (2007) · Translational Lung Cancer Research · doi:10.21037/tlcr.2017.03.02 · Cited by 15
“In these patients, IFN-γ levels correlated with prognosis, suggesting that imatinib-mediated activation of NK cells may be playing a clinically meaningful role (60,61).”
BackgroundHar-Noy, M., Zeira, M., Weiss, L., & Slavin, S. (2008) · Leukemia Research · doi:10.1016/j.leukres.2008.05.007 · Cited by 13
“Anti-tumor immunity is mediated by adaptive and innate components of cellular immunity [52–54].”
Backgroundc-Abl Modulates Tumor Cell Sensitivity to Antibody-Dependent Cellular Cytotoxicity
Murray, J. C., Aldeghaither, D. S., Wang, S., Nasto, R. E., Jablonski, S. A., Tang, Y., & Weiner, L. M. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0083 · Cited by 15
“Imatinib has complex effects on human NK cells (31, 43), and has been shown to indirectly enhance NK-cell activity, independent of the effects we demonstrate on tumor cell sensitivity to ADCC.”
BackgroundKamenz, T. (2006) · World Journal of Gastroenterology · doi:10.3748/wjg.v12.i10.1583 · Cited by 13
“NK cell activation [ 16 ] and downregulates telomerase”
BackgroundZhou, S., Tanaka, K., O’Keeffe, M. A., Miao, Q., El‐Assaad, F., Weaver, J. C., Chen, G., Weatherall, C. J., Wang, Y., Giannakopoulos, B., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0151638 · Cited by 11
“The expression and release of IFN-γ by DC-stimulated NK cells is important in combating pathogens while adaptive immune responses are being primed, and CD117 is important for these responses [20].”
BackgroundKälsch, A.-I., Soboletzki, M., Schmitt, W. H., van der Woude, F. J., Hochhaus, A., Yard, B. A., & Birck, R. (2008) · Clinical & Experimental Immunology · doi:10.1111/j.1365-2249.2007.03572.x · Cited by 12
Osaki, T., Saito, H., Fukumoto, Y., Yamada, Y., Fukuda, K., Tatebe, S., Tsujitani, S., & Ikeguchi, M. (2008) · Diseases of the Esophagus · doi:10.1111/j.1442-2050.2008.00855.x · Cited by 12
GM-CSF Inhibits c-Kit and SCF Expression by Bone Marrow-Derived Dendritic Cells
Seijas, A. B. B., Simonetti, S., Vitale, S., Runci, D., Quinci, A. C., Soriani, A., Criscuoli, M., Filippi, I., Naldini, A., Sacchetti, F. M., et al. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00147 · Cited by 13
Xiao, L., Zhou, J., Liu, H., Zhou, Y., Chen, W., Cui, W., & Zhao, Y. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.679262 · Cited by 14
Advances in Cellular Therapy for the Treatment of Thyroid Cancer
Papewalis, C., Ehlers, M., & Schott, M. (2010) · Journal of Oncology · doi:10.1155/2010/179491 · Cited by 10
“On the other hand, TKIs’ affect DCs to activate NK cells [156–158].”
BackgroundThe dilemma of anticancer therapy: tumor-specific versus immune effects
Zitvogel, L., & Kroemer, G. (2008) · Blood · doi:10.1182/blood-2008-09-176693 · Cited by 11
Dendritic Cell-Based Tumor Vaccinations in Epithelial Ovarian Cancer: A Systematic Review
Tanyi, J. L., & Chu, C. (2012) · Immunotherapy · doi:10.2217/imt.12.100 · Cited by 11
CSPG4 Expression in GIST Is Associated with Better Prognosis and Strong Cytotoxic Immune Response
de Nonneville, A. T., Finetti, P., Picard, M., Monneur, A., Pantaleo, M. A., Astolfi, A., Ostrowski, J., Birnbaum, D., Mamessier, É., & Bertucci, F. (2022) · Cancers · doi:10.3390/cancers14051306 · Cited by 10
“The oncolytic action of imatinib also partly relies on indirect effects of immune cell actions, notably CD8+ T-cells [15] and NK-cells [22].”
BackgroundMorandi, F., Amoroso, L., Dondero, A., Castriconi, R., Parodi, S., Luksch, R., Casale, F., Castellano, A., Garaventa, A., Moretta, A., et al. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1468953 · Cited by 11
Geisler, K., Reischer, A., Kroeger, I., Jacobs, B., Meinhardt, K., Bauer, R., Ryffel, B., Mackensen, A., & Ullrich, E. (2014) · Oncology Reports · doi:10.3892/or.2014.3070 · Cited by 10
“Apart from its direct cell-autonomous effect, additional immunostimulation, mediated by host cells such as dendritic cells (DCs) and natural killer (NK) cells, was demonstrated in a murine B16F10 melanoma model (8).”
BackgroundMethodInfluentialLi, Y., Li, Y., Xiang, B., Tian, X., Shi, Q., Liu, F., Lin, T., & Wei, G. (2022) · Journal of Oncology · doi:10.1155/2022/4544773 · Cited by 9
“In order to explore the potential of immunotherapy strategy on WT, cytokine therapy-induced NK cell functions are likely to affect the clinical course of several human malignancies, including neuroblastoma, gastrointestinal sarcoma, and kidney and lung carcinoma [34, 35].”
BackgroundHighlights of the society for immunotherapy of cancer (SITC) 27th annual meeting
Stroncek, D. F., Melief, C. J. M., Castiello, L., Cesano, A., Cheever, M. A., Civini, S., Comin-Anduix, B., Gajewski, T. F., Greenberg, P. D., Kaliński, P., et al. (2013) · Journal for ImmunoTherapy of Cancer · doi:10.1186/2051-1426-1-4 · Cited by 10
Held, S. A. E., Duchardt, K. M., Tenzer, S., Rückrich, T., von Schwarzenberg, K., Bringmann, A., Kurts, C., Schild, H., Driessen, C., Brossart, P., et al. (2012) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-012-1373-7 · Cited by 7
“[41], treatment of mice with IM resulted in a higher NK cell-mediated recognition and elimination of malignant cells.”
BackgroundMolecular response prediction in gastrointestinal stromal tumors
Cassier, P. A., & Blay, J. (2010) · Targeted Oncology · doi:10.1007/s11523-010-0134-9 · Cited by 7
“Borg et al suggested that this discrepancy may be explained by an immunologic effect of IM, which induces dendritic cell-mediated natural killer cell-activation [38].”
BackgroundVairy, S., Teuff, G. L., Bautista, F. J., Carli, É. D., Bertozzi, A., Pagnier, A., Fouyssac, F., Nysom, K., Aerts, I., Leblond, P., et al. (2020) · Neuro-Oncology Advances · doi:10.1093/noajnl/vdaa075 · Cited by 9
Cytokines reinstate NK cell–mediated cancer immunosurveillance
Zitvogel, L., & Kroemer, G. (2014) · Journal of Clinical Investigation · doi:10.1172/jci78531 · Cited by 7
Liu, X., Zhou, Q., Xu, Y., Chen, M., Zhao, J., & Wang, M. (2017) · Oncotarget · doi:10.18632/oncotarget.21160 · Cited by 7
“Similar findings have been observed in clinical studies that imatinib treatment enhanced IFNγ secretion in GIST patients [86, 87].”
BackgroundResult
Metadata
- Authors
- Borg, C., Terme, M., Taïeb, J., Ménard, C., Flament, C., Robert, C., Maruyama, K., Wakasugi, H., Angevin, E., Thielemans, K., Cesne, A. L., Chung-Scott, V., Lazar, V., Tchou, I., Crépineau, F., Lemoine, F., Bernard, J., Fletcher, J. A., Turhan, A., Blay, J.-Y., Spatz, A., Emile, J.-F., Heinrich, M. C., Mécheri, S., Tursz, T., & Zitvogel, L.
- Affiliations
- Inserm (FR)
- National Cancer Centre Japan (JP)
- Vrije Universiteit Brussel (BE)
- Institut Gustave Roussy (FR)
- Institut Jean Godinot (FR)
- Harvard University (US)
- Hospices Civils de Lyon (FR)
- Assistance Publique – Hôpitaux de Paris (FR)
- Oregon Health & Science University (US)
- Corresponding author
- Zitvogel, Laurence
- ORCID
- Venue
- Journal of Clinical Investigation
- Published
- 2004-08-01
- Volume
- 114
- Issue
- 3
- Pages
- 379-388
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC489961
- OpenAlex
- W2161785083
- Cited by
- 302
- References
- 35
- Citations by year
- 2026: 5 · 2025: 1 · 2024: 4 · 2023: 3 · 2022: 11 · 2021: 8 · 2020: 13 · 2019: 9 · 2018: 4 · 2017: 11 · 2016: 14 · 2015: 19 · 2014: 16 · 2013: 24 · 2012: 19
- FWCI
- 16.77
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Dépôt institutionnel de l'Université libre de Bruxelles (Université Libre de Bruxelles) (submittedVersion)
- VUBIR (Vrije Universiteit Brussel) (submittedVersion)
- Funders
- Novartis Pharmaceuticals Corporation
- Institut National de la Santé et de la Recherche Médicale
- Hospices Civils de Lyon
- Topics
- Health Sciences › Medicine › Gastroenterology › Gastrointestinal Tumor Research and Treatment
- Life Sciences › Immunology and Microbiology › Immunology › Immune Cell Function and Interaction
- Life Sciences › Immunology and Microbiology › Immunology › Mast cells and histamine
- Keywords
- imatinib mesylate, gastrointestinal stromal tumor, NK cell activation, dendritic cells, interferon-gamma, antitumor immunity, PDGF receptor, stem cell factor
- MeSH terms
- Imatinib Mesylate, Animals, Antineoplastic Agents, Benzamides, Dendritic Cells, Enzyme Inhibitors, Female, Gastrointestinal Neoplasms, Humans, Interferon-gamma, Killer Cells, Natural, Leukocytes, Mononuclear, Longitudinal Studies, Mice, Inbred C57BL, Mutation, Piperazines, Protein-Tyrosine Kinases, Pyrimidines, Gene Expression Regulation, Neoplastic, Case-Control Studies, Mice, SCID, Stromal Cells, Receptors, Platelet-Derived Growth Factor, Mice, Knockout, Neutrophil Activation, Coculture Techniques, Proto-Oncogene Proteins c-kit, Receptor Protein-Tyrosine Kinases, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.